Phase 3 Alzheimer's Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have a confirmed diagnosis of Alzheimer's disease at the mild (stage 4) or moderate (stage 5) dementia stage, diagnosed according to the most recent official criteria from the National Institute on Aging and Alzheimer's Association (NIA-AA).
- People whose score on a standard memory and thinking test (called the MMSE) falls between 12 and 22 at the time of initial screening.
- People who have a designated caregiver who spends around 10 or more hours per week with them, is willing to attend all study visits, and agrees to help monitor the participant's condition and medication.
- People who are taking Alzheimer's medications (AChEIs and/or memantine) must have been on a stable dose for at least 12 weeks before screening, with an agreement to keep that dose unchanged throughout the study.
Who may not be able to join:
- People who have significant or serious medical conditions that could affect their safety or the reliability of the study results — including any level of liver problems, difficulty passing urine, active gallbladder disease, moderate-to-severe kidney problems, or unstable high blood pressure or abnormally fast heart rate.
- People who have a primary psychiatric diagnosis such as major depression, schizoaffective disorder, or bipolar disorder, or who have severe psychiatric symptoms that could affect cognitive testing or study completion.
- People who have a history of schizophrenia or long-term psychosis, who have previously been treated with a drug called KarXT, or who have received disease-modifying anti-amyloid treatments for Alzheimer's disease within the past 6 months before screening.
- People whose brain MRI scan at screening shows significant findings unrelated to Alzheimer's disease, or findings that could affect safety or interfere with the study.
- Additional criteria not listed here may also apply (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Bristol-Myers Squibb, Bristol-Myers Squibb
Phone: 855-907-3286
Australian sites
+61 2 8566 1500
61 2 8960 7788
+61 3 9546 0009
+61 8 6317 9472
61 2 8382 4983
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
5 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Change from baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale 11 (ADAS-Cog11); Clinician's Interview-Based Impression Plus Caregiver Input (CIBIC+)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.